Literature DB >> 16762028

Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells.

Yonsu Son1, Tomoki Ito, Yoshio Ozaki, Tsutomu Tanijiri, Takashi Yokoi, Kengo Nakamura, Masashi Takebayashi, Ryuichi Amakawa, Shirou Fukuhara.   

Abstract

Prostaglandin E2 (PGE2), a major lipid derived from the metabolism of arachidonic acid, is an environmentally bioactive substance produced by inflammatory processes and acts as a cAMP up-regulator that plays an important role in immune responses. It has been reported that PGE2 has the ability to inhibit the production of interleukin-12 by myeloid dendritic cells (MDCs) and macrophages, and then induce preferential T helper type 2 (Th2) cell responses. However, little is known of the function of PGE2 for plasmacytoid dendritic cells (PDCs), which may contribute to the innate and adaptive immune response to viral infection, allergy and autoimmune diseases. In the present study, we compared the biological effect of PGE2 on human PDCs and MDCs. PGE2 caused the death of PDCs but MDCs survived. Furthermore, we found that, whereas PGE2 inhibited interferon-alpha production by PDCs in response to virus or cytosine-phosphate-guanosine, it inhibited interleukin-12 production by MDCs in response to lipopolysaccharide (LPS) or poly(I:C). Although both virus-stimulated PDCs and LPS-stimulated MDCs preferentially induced the development of interferon-gamma-producing Th1 cells, pretreatment with PGE2 led both DC subsets to attenuate their Th1-inducing capacity. These findings suggest that PGE2 represents a negative regulator on not only MDCs but also PDCs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16762028      PMCID: PMC1782338          DOI: 10.1111/j.1365-2567.2006.02402.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  45 in total

1.  Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6.

Authors:  Gaetan Jego; A Karolina Palucka; Jean-Philippe Blanck; Cecile Chalouni; Virginia Pascual; Jacques Banchereau
Journal:  Immunity       Date:  2003-08       Impact factor: 31.745

2.  Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells.

Authors:  Tomoki Ito; Holger Kanzler; Omar Duramad; Wei Cao; Yong-Jun Liu
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

3.  Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions.

Authors:  Hedi Harizi; Monique Juzan; Vincent Pitard; Jean-François Moreau; Norbert Gualde
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

4.  Cutting edge: histamine inhibits IFN-alpha release from plasmacytoid dendritic cells.

Authors:  Alessandra Mazzoni; Cynthia A Leifer; Gregory E D Mullen; Margaret N Kennedy; Dennis M Klinman; David M Segal
Journal:  J Immunol       Date:  2003-03-01       Impact factor: 5.422

5.  Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets.

Authors:  Thomas Luft; Michael Jefford; Petra Luetjens; Tracey Toy; Hubertus Hochrein; Kelly-Anne Masterman; Charlie Maliszewski; Ken Shortman; Jonathan Cebon; Eugene Maraskovsky
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

6.  Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells.

Authors:  Jean-François Fonteneau; Marie Larsson; Anne-Sophie Beignon; Kelli McKenna; Ida Dasilva; Ali Amara; Yong-Jun Liu; Jeffrey D Lifson; Dan R Littman; Nina Bhardwaj
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.

Authors:  Simon Rothenfusser; Veit Hornung; Maha Ayyoub; Stefanie Britsch; Andreas Towarowski; Anne Krug; Anja Sarris; Norbert Lubenow; Daniel Speiser; Stefan Endres; Gunther Hartmann
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

Review 8.  Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent.

Authors:  Ed C Lavelle; Andrew Jarnicki; Edel McNeela; Michelle E Armstrong; Sarah C Higgins; Olive Leavy; Kingston H G Mills
Journal:  J Leukoc Biol       Date:  2004-01-02       Impact factor: 4.962

9.  Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets.

Authors:  Tomoki Ito; Ryuichi Amakawa; Tsuneyasu Kaisho; Hiroaki Hemmi; Kenichirou Tajima; Kazutaka Uehira; Yoshio Ozaki; Hideyuki Tomizawa; Shizuo Akira; Shirou Fukuhara
Journal:  J Exp Med       Date:  2002-06-03       Impact factor: 14.307

10.  Systemic lupus erythematosus and the type I interferon system.

Authors:  Lars Rönnblom; Gunnar V Alm
Journal:  Arthritis Res Ther       Date:  2003-01-20       Impact factor: 5.156

View more
  13 in total

1.  E-prostanoid 3 receptor deletion improves pulmonary host defense and protects mice from death in severe Streptococcus pneumoniae infection.

Authors:  David M Aronoff; Casey Lewis; Carlos H Serezani; Kathryn A Eaton; Deepti Goel; John C Phipps; Marc Peters-Golden; Peter Mancuso
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

Review 2.  cAMP during HIV infection: friend or foe?

Authors:  Maria E Moreno-Fernandez; Cesar Mauricio Rueda; Paula A Velilla; Maria Teresa Rugeles; Claire A Chougnet
Journal:  AIDS Res Hum Retroviruses       Date:  2011-11-02       Impact factor: 2.205

3.  The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.

Authors:  Sara Trabanelli; Darina Očadlíková; Marilena Ciciarello; Valentina Salvestrini; Mariangela Lecciso; Camilla Jandus; Richard Metz; Cecilia Evangelisti; Lisa Laury-Kleintop; Pedro Romero; George C Prendergast; Antonio Curti; Roberto M Lemoli
Journal:  J Immunol       Date:  2014-01-03       Impact factor: 5.422

4.  C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes.

Authors:  Deanna M Santer; Brian E Hall; Thaddeus C George; Stephanie Tangsombatvisit; Chih Long Liu; Peter D Arkwright; Keith B Elkon
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

Review 5.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

6.  IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis.

Authors:  Carine Bouffi; Claire Bony; Gabriel Courties; Christian Jorgensen; Danièle Noël
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

7.  Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha.

Authors:  Isabelle Bekeredjian-Ding; Meike Schäfer; Evelyn Hartmann; Ralph Pries; Marijo Parcina; Philip Schneider; Thomas Giese; Stefan Endres; Barbara Wollenberg; Gunther Hartmann
Journal:  Immunology       Date:  2009-11       Impact factor: 7.397

8.  Prostaglandin E2 modulates dendritic cell function during chlamydial genital infection.

Authors:  Wei Liu; Kathleen Ann Kelly
Journal:  Immunology       Date:  2007-08-03       Impact factor: 7.397

9.  Activity of the cyclooxygenase 2-prostaglandin-E prostanoid receptor pathway in mice exposed to house dust mite aeroallergens, and impact of exogenous prostaglandin E2.

Authors:  Aida Herrerias; Rosa Torres; Mariona Serra; Alberto Marco; Laura Pujols; César Picado; Fernando de Mora
Journal:  J Inflamm (Lond)       Date:  2009-10-30       Impact factor: 4.981

Review 10.  The multiple faces of prostaglandin E2 G-protein coupled receptor signaling during the dendritic cell life cycle.

Authors:  Sandra De Keijzer; Marjolein B M Meddens; Ruurd Torensma; Alessandra Cambi
Journal:  Int J Mol Sci       Date:  2013-03-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.